首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >The association between COPD and heart failure risk: a review
【24h】

The association between COPD and heart failure risk: a review

机译:慢性阻塞性肺病与心力衰竭风险之间的关系

获取原文
           

摘要

Abstract: Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective ?1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled ?2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.
机译:摘要:慢性阻塞性肺疾病(COPD)在临床实践中通常与心力衰竭(HF)相关,因为它们具有相同的致病机制。两种情况均导致明显的发病率和死亡率。因此,合并COPD和HF的预后比任何一种疾病都要差。尽管如此,通常仅诊断出其中之一。应通过临床检查和包括血浆利钠肽,肺功能检查和超声心动图在内的其他检查方法积极搜索每种疾病。 COPD和HF的组合存在许多治疗挑战。在患有HF并存COPD的稳定患者中,不应否认选择性β1-受体阻滞剂的有益作用。此外,他汀类药物,血管紧张素转化酶抑制剂和血管紧张素受体阻滞剂可能会降低COPD患者的发病率和死亡率。此外,建议使用吸入的β2-激动剂治疗HF患者的COPD。最后,在常规治疗中增加了无创通气,可改善因急性肺水肿导致COPD或HF高碳酸血症加重而导致急性呼吸衰竭的患者的预后。建立一种综合,综合的方法来管理这些合并症似乎是一种适当的策略。需要进行其他研究,以提供有关COPD和HF患者的发病机理和治疗方法的新数据,目的是试图改善这些患者的生活质量和生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号